Cat. No.: HY-12651A

Primaquine

6 Cited Publications

Customer Review

Based on 6 publication(s) in Google Scholar

Primaquine is a potent antimalaria agent and a potent gametocytocide in falciparum malaria. Primaquine prevents relapse in vivax and ovale malaria.

For research use only. We do not sell to patients.

Purity: 97.68%
CAS No.: 90-34-6
Formula: C₁₅H₂₁N₃O
Molecular Weight:259.35

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Primaquine Chemical Structure

CAS No.: 90-34-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Primaquine is a potent antimalaria agent and a potent gametocytocide in falciparum malaria. Primaquine prevents relapse in vivax and ovale malaria^[1]^[2].

IC₅₀ & Target

Plasmodium

All Parasite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>100 μM Compound: 1, PQ	Cytotoxicity against human A549 cells after 72 hrs Cytotoxicity against human A549 cells after 72 hrs	[PMID: 19799426]
Caco-2	IC₅₀	48 μM Compound: 1	Antitumor activity against human Caco-2 cells after 48 hours hrs by SRB assay Antitumor activity against human Caco-2 cells after 48 hours hrs by SRB assay	[PMID: 19896373]
HCT-116	IC₅₀	20 μM Compound: Primaquine	Cytostatic activity against human HCT116 cells Cytostatic activity against human HCT116 cells	[PMID: 19581098]
HCT-116	IC₅₀	20.78 μM Compound: PQ	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
HEK-293T	IC₅₀	37.64 μM Compound: PQ	Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
Hepatocyte	IC₅₀	970 μM Compound: 19 Primaquine	Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes	[PMID: 15225721]
Hepatocyte	IC₅₀	75.7 nM Compound: Primaquine	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
Hepatocyte	IC₅₀	0.64 μM Compound: Primaquine	Antimalarial activity against Plasmodium yoelii 265 sporozoites in primary mice (Mus musculus) hepatocytes after 48 hrs Antimalarial activity against Plasmodium yoelii 265 sporozoites in primary mice (Mus musculus) hepatocytes after 48 hrs	[PMID: 18456502]
Hepatocyte	CC₅₀	54 μM Compound: PQ	Cytotoxicity against human primary hepatocytes after 48 hrs by MTT assay Cytotoxicity against human primary hepatocytes after 48 hrs by MTT assay	[PMID: 29754074]
Hepatocyte	CC₅₀	54.21 μM Compound: PQ	Cytotoxicity against human primary hepatocytes assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human primary hepatocytes assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30199706]
Hepatocyte	CC₅₀	>50 μM Compound: Primaquine	Cytotoxicity against Cynomolgous monkey hepatocytes harboring Simian virus assessed as reduction in cell viability administered for 3 hrs followed by replacement with fresh medium containing compound for every 24 hrs by DAPI staining based analysis Cytotoxicity against Cynomolgous monkey hepatocytes harboring Simian virus assessed as reduction in cell viability administered for 3 hrs followed by replacement with fresh medium containing compound for every 24 hrs by DAPI staining based analysis	[PMID: 37857143]
HepG2	IC₅₀	7.5 μM Compound: Primaquine	Antiplasmodial activity against liver stage of Plasmodium berghei ANKA infected in human HepG2 cells Antiplasmodial activity against liver stage of Plasmodium berghei ANKA infected in human HepG2 cells	[PMID: 23806111]
HepG2	IC₅₀	<1 μM Compound: Primaquine	Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin	[PMID: 23927658]
HepG2	CC₅₀	6.1 μM Compound: Primaquine	Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay	[PMID: 25791675]
HepG2	IC₅₀	1160 nM Compound: Primaquine	Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis	[PMID: 25791675]
HepG2	IC₅₀	101 μM Compound: PQ	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	[PMID: 28939120]
HepG2	CC₅₀	120.03 μM Compound: PQ	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30199706]
HepG2	CC₅₀	69.8 μM Compound: PQ	Cytotoxicity against human HepG2 cells expressing CD81 assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells expressing CD81 assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30199706]
HT-29	IC₅₀	69.7 μM Compound: 1	Antitumor activity against human HT-29 cells after 48 hours hrs by SRB assay Antitumor activity against human HT-29 cells after 48 hours hrs by SRB assay	[PMID: 19896373]
Huh-7	IC₅₀	2 μM Compound: 1, PQ	Antiplasmodial activity against liver-stage GFP expressing Plasmodium berghei sporozoites infected in human HuH7 cells assessed as inhibition of parasite schizonts development after 48 hrs by FACS analysis Antiplasmodial activity against liver-stage GFP expressing Plasmodium berghei sporozoites infected in human HuH7 cells assessed as inhibition of parasite schizonts development after 48 hrs by FACS analysis	[PMID: 19799426]
Huh-7	IC₅₀	7.5 μM Compound: 3, PQ	Antiplasmodial activity against Plasmodium berghei liver stage form transfected in human Huh-7 cells assessed as cell viability after 48 hrs by luciferase reporter gene assay Antiplasmodial activity against Plasmodium berghei liver stage form transfected in human Huh-7 cells assessed as cell viability after 48 hrs by luciferase reporter gene assay	[PMID: 23273038]
Huh-7	IC₅₀	8 μM Compound: PQ	Antiplasmodial activity against liver stage of Plasmodium berghei expressing GFP-Luc infected in HuH7 cells incubated at 1 hr prior to infection followed by compound replenisment at 24 hrs post-infection measured after 48 hrs by Alamar blue assay Antiplasmodial activity against liver stage of Plasmodium berghei expressing GFP-Luc infected in HuH7 cells incubated at 1 hr prior to infection followed by compound replenisment at 24 hrs post-infection measured after 48 hrs by Alamar blue assay	[PMID: 23290049]
Huh-7	IC₅₀	7.5 μM Compound: 1, PQ	Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells co-expressing GFP-Luccon treated for 1 hr prior to infection followed by 24 hrs after compound washout measured after 48 hrs post-infection by Alamar Blue assay Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells co-expressing GFP-Luccon treated for 1 hr prior to infection followed by 24 hrs after compound washout measured after 48 hrs post-infection by Alamar Blue assay	[PMID: 23701465]
Huh-7	IC₅₀	7.5 μM Compound: Primaquine	Antiplasmodial activity against liver stage of Plasmodium berghei expressing GFP infected in human Huh7 cells by luminescence assay Antiplasmodial activity against liver stage of Plasmodium berghei expressing GFP infected in human Huh7 cells by luminescence assay	[PMID: 23806111]
Huh-7	IC₅₀	7500 nM Compound: PQ	Antiplasmodial activity against liver stage of Plasmodium berghei infected in human HuH7 cells assessed as parasite growth inhibition incubated for 1 hr prior to parasite infection measured after 48 hrs Antiplasmodial activity against liver stage of Plasmodium berghei infected in human HuH7 cells assessed as parasite growth inhibition incubated for 1 hr prior to parasite infection measured after 48 hrs	[PMID: 24020770]
Huh-7	IC₅₀	7.5 μM Compound: Primaquine	Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei expressing luciferase and GFP infected in human HuH7 cells assessed as inhibition of parasite development incubated for 1 hr prior to parasite infection measured after 48 hrs by Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei expressing luciferase and GFP infected in human HuH7 cells assessed as inhibition of parasite development incubated for 1 hr prior to parasite infection measured after 48 hrs by	[PMID: 24125849]
Huh-7	IC₅₀	7500 nM Compound: 2, PQ	Antimalarial activity against liver stage of Plasmodium berghei infected in human Huh7 cells after 48 hrs by luciferase assay Antimalarial activity against liver stage of Plasmodium berghei infected in human Huh7 cells after 48 hrs by luciferase assay	[PMID: 24900781]
Huh-7	IC₅₀	3.4 μg/mL Compound: Primaquine	Antimalarial activity against liver stage of Plasmodium berghei infected in human Huh7 cells assessed as reduction in parasite load treated after 2 hrs of infection for 46 hrs by luciferase assay Antimalarial activity against liver stage of Plasmodium berghei infected in human Huh7 cells assessed as reduction in parasite load treated after 2 hrs of infection for 46 hrs by luciferase assay	[PMID: 25103602]
Huh-7	IC₅₀	7500 nM Compound: PQ	Antimalarial activity against Plasmodium berghei infected in human HuH7 cells assessed as inhibition of liver cell infection Antimalarial activity against Plasmodium berghei infected in human HuH7 cells assessed as inhibition of liver cell infection	[PMID: 25593097]
Huh-7	IC₅₀	8.428 μM Compound: PQ	Antiplasmodial activity against liver-stage of Plasmodium berghei expressing firefly luciferase infected in human Huh-7 cells after 48 hrs by bioluminescence assay Antiplasmodial activity against liver-stage of Plasmodium berghei expressing firefly luciferase infected in human Huh-7 cells after 48 hrs by bioluminescence assay	[PMID: 26142491]
Huh-7	IC₅₀	9.5 μM Compound: 1	Antiplasmodial activity against liver stage Plasmodium berghei infected in Huh7 cells assessed as inhibition of parasite infection incubated for 1 hr prior to infection measured at 24 hrs by luciferase reporter gene assay Antiplasmodial activity against liver stage Plasmodium berghei infected in Huh7 cells assessed as inhibition of parasite infection incubated for 1 hr prior to infection measured at 24 hrs by luciferase reporter gene assay	[PMID: 26968650]
Huh-7	IC₅₀	2.4 μM Compound: 12; PQ	Antimalarial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition by bioluminescence assay Antimalarial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition by bioluminescence assay	[PMID: 34242031]
Huh-7	IC₅₀	7.5 μM Compound: 1, PQ	Antiplasmodial activity against liver stage of Plasmodium berghei sporozoites expressing firefly luciferase infected in human Huh7 cells assessed as inhibition of parasite development treated 1 hr prior to infection followed by compound replenisment at 24 Antiplasmodial activity against liver stage of Plasmodium berghei sporozoites expressing firefly luciferase infected in human Huh7 cells assessed as inhibition of parasite development treated 1 hr prior to infection followed by compound replenisment at 24	10.1039/C2MD20113E
MCF7	IC₅₀	28 μM Compound: Primaquine	Cytostatic activity against human MCF7 cells Cytostatic activity against human MCF7 cells	[PMID: 19581098]
MCF7	IC₅₀	6.9 μM Compound: 1	Antitumor activity against human MCF7 cells after 48 hours hrs by SRB assay Antitumor activity against human MCF7 cells after 48 hours hrs by SRB assay	[PMID: 19896373]
MCF7	IC₅₀	26.6 μM Compound: PQ	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
NCI-H460	IC₅₀	30 μM Compound: Primaquine	Cytostatic activity against human H460 cells Cytostatic activity against human H460 cells	[PMID: 19581098]
RAW264.7	IC₅₀	38.7 μg/mL Compound: 2, PQ	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 21141892]
SW-620	IC₅₀	>=100 μM Compound: Primaquine	Cytostatic activity against human SW620 cells Cytostatic activity against human SW620 cells	[PMID: 19581098]
SW-620	IC₅₀	9.2 μM Compound: PQ	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
Vero	IC₅₀	339.7 μM Compound: PQ, primaquine	Cytotoxicity against african green monkey Vero cells assessed as [3H]hypoxanthine incorporation after 48 hrs Cytotoxicity against african green monkey Vero cells assessed as [3H]hypoxanthine incorporation after 48 hrs	[PMID: 18653332]
Vero	IC₅₀	≤23.8 μg/mL Compound: 1, PQ	Cytotoxicity against African green monkey Vero cells by neutral red uptake assay Cytotoxicity against African green monkey Vero cells by neutral red uptake assay	10.1039/C0MD00267D

In Vitro

Primaquine significantly decreases the cell proliferation of live breast cancer cells, and shows no inhibitory effect on the proliferation of MCF-7 (ER+^{) and MDA-MB-453 (HER}2+^{) cells. Primaquine inhibits the growth, migration, and colony formation of breast cancer cells in vitro^[3].}

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

MDA-MB-231, HCC1937 cells, MCF-7, and MDA-MB-453 cells
Concentration:

5 μM, 10 μM, 20 μM, 40 μM, 80 μM, 100 μM, 120 μM, and 150 μM
Incubation Time:

24 h
Result:

Decreases breast cancer cell viability.

In Vivo

Primaquine (5-25 mg/kg; p.o; daily; for 3 days) demonstrates no bioluminescence liver signal and no blood stage parasitaemia^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male 6-week-old C57BL/6 albino mice with sporozoite inoculation^[2]
Dosage:

5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, and 25 mg/kg
Administration:

p.o; daily; for 3 days
Result:

No blood stage parasitaemia was observed.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 90-34-6
Appearance <25°C Solid,>25°C Liquid
Molecular Weight 259.35
Formula C₁₅H₂₁N₃O
Color Light brown to yellow
SMILES

CC(NC1=C2N=CC=CC2=CC(OC)=C1)CCCN
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (6)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Network Medicine-Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD-L1 Expression via Targeting SPOP in Cancer. [Abstract]

2024 Nov 5:e2410285. PMID: 39499771
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
ACS Omega

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]

2024 Feb 28;9(10):11870-11882. PMID: 38496939
Adv Ther (Weinh)

05 October 2021.
Biomed Pharmacother

As a novel ferroptosis inhibitor, primaquine alleviates I/R-induced retinal neuron death via increasing GSTA1 activity. [Abstract]

2026 Feb:195:118973. PMID: 41529513
Ann Transl Med

Integrative identification of the pathogenic role of a novel G6PD missense mutation c.697G>C. [Abstract]

2021 Feb;9(3):194. PMID: 33708821

Solvent & Solubility

In Vitro:

DMSO : ≥ 200 mg/mL (771.16 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.8558 mL

19.2790 mL

38.5579 mL

5 mM

0.7712 mL

3.8558 mL

7.7116 mL

10 mM

0.3856 mL

1.9279 mL

3.8558 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (8.02 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ashley EA, et al. Primaquine: the risks and the benefits. Malar J. 2014 Nov 3;13:418. [Content Brief]

[2]. Qigui Li, et al. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections. Malar J. 2014 Apr 14:13:141. [Content Brief]

[3]. Ji-Hyang Kim, et al. Primaquine Inhibits the Endosomal Trafficking and Nuclear Localization of EGFR and Induces the Apoptosis of Breast Cancer Cells by Nuclear EGFR/Stat3-Mediated c-Myc Downregulation. Int J Mol Sci. 2021 Nov 30;22(23):12961. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8558 mL	19.2790 mL	38.5579 mL	96.3948 mL
	5 mM	0.7712 mL	3.8558 mL	7.7116 mL	19.2790 mL
	10 mM	0.3856 mL	1.9279 mL	3.8558 mL	9.6395 mL
	15 mM	0.2571 mL	1.2853 mL	2.5705 mL	6.4263 mL
	20 mM	0.1928 mL	0.9639 mL	1.9279 mL	4.8197 mL
	25 mM	0.1542 mL	0.7712 mL	1.5423 mL	3.8558 mL
	30 mM	0.1285 mL	0.6426 mL	1.2853 mL	3.2132 mL
	40 mM	0.0964 mL	0.4820 mL	0.9639 mL	2.4099 mL
	50 mM	0.0771 mL	0.3856 mL	0.7712 mL	1.9279 mL
	60 mM	0.0643 mL	0.3213 mL	0.6426 mL	1.6066 mL
	80 mM	0.0482 mL	0.2410 mL	0.4820 mL	1.2049 mL
	100 mM	0.0386 mL	0.1928 mL	0.3856 mL	0.9639 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Primaquine

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Antiparasitic Compound library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Primaquine

All Parasite Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Primaquine

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Antiparasitic Compound library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Primaquine

All Parasite Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Primaquine Related Classifications

HY-12651A Related Classifications